With the continuous development of molecular detection techniques,the diagnostic rate of hematological diseases is rising.The drug treatment of hematological diseases,especially malignant hematological diseases,also develops rapidly,benefiting more and more patients clinically.The standardized diagnosis and treatment of hematological diseases and the rational drug use,especially the new immunotherapy and targeted therapy drugs,have been widely concerned by clinicians and patients.Off-label drugs use is common in clinical practice.The implementation of the Law on Doctors of the People's Republic of China effective on March 2022 provides a legal basis for off-label drug use in China.Expert Consensus on Off-Label Drug Use of Liaoning Province in Hematological Diseases(2023 Edition)has compiled a list of off-label drugs for chemotherapy,targeted drugs and supportive care for hematological disorders.According to the evidence-based evaluation method developed by the expert group,this list is condensed through literature review,evidence quality evaluation grading and expert argumentation,to provide evidence-based support and reference for clinical medication.
国家科技期刊平台
NSTL
万方数据
